The 10-day program isn't the lesser option. It's the smart first step in a longer-term healing journey — and understanding why changes how you approach recovery.
When patients receive information about the Lyme Re-code programs at the Immunotherapy Institute, a common reaction is to frame the choice as a comparison: 10-day versus 18-day, shorter versus longer, less versus more.
That framing misses what's actually happening.
This isn't two versions of the same thing at different price points. It's a staged approach to chronic Lyme recovery — and understanding the logic behind the staging changes how you think about your own healing journey.
The 10-Day Program: What It Actually Is
The 10-day Treg apheresis program is a focused, foundational protocol centered on immune recalibration. It is not a "lite" version of the 18-day program. It is the foundation everything else builds on.
A body that has been chronically inflamed and immunologically dysregulated for years — sometimes decades — cannot absorb aggressive intervention well. Attempting to do everything at once, before the immune system has been restored to a regulatory state, means you're applying powerful therapies to a system that can't respond to them the way it's supposed to.
The 10-day program meets the body where it is. It restores Treg function — the immune system's ability to regulate itself — and creates the conditions in which genuine recovery becomes possible. The program includes a buffer day after the final treatment for monitoring and discharge consultation, so patients leave prepared and supported.
What Patients Typically Gain
Most patients completing the 10-day program report: reduced systemic inflammation, improved energy and mental clarity, better immune signaling, and — critically — a body that now responds to other supportive approaches the way it was supposed to all along. Supplements that had minimal effect before start working. Sleep improves. The rollercoaster of flares begins to stabilize.
This happens because the regulatory thermostat has been reset. The immune system can finally modulate itself. That's a different physiological state than the one most chronic Lyme patients have been living in for years.
The 10-day program doesn't just help patients feel better. It changes the internal environment so that everything that follows — including the 18-day program — works more effectively.
The 18-Day Program: A Powerful Round Two
The 18-day program is a more comprehensive protocol that includes systemic perfusion hyperthermia (up to 42°C / 107.6°F) and a second round of apheresis. It's positioned as a powerful "round two" option for patients who have already completed the 10-day and are returning to do deeper work in a cleaner internal environment.
When a patient returns for the 18-day having already done the 10-day, the immune system is in a fundamentally different state. The second round of apheresis lands on a much better-prepared substrate — removing the remaining inflammatory debris from a body that has already regained regulatory function. The hyperthermia works with a regulated immune system instead of against a chaotic one. The therapy goes deeper because the body is ready for it.
The Roadmap Visualized
- Step 1 — 10-day program: Immune foundation restored. Treg function recalibrated. Inflammatory baseline reduced.
- Step 2 — Recovery and integration at home: The body integrates the shift. Most patients notice continued improvement over the weeks following the program.
- Step 3 — Return for the 18-day program: On a recalibrated foundation, the deeper interventions — hyperthermia and a second apheresis — achieve results that wouldn't have been possible in the original dysregulated state.
This is a long-term partnership with the Immunotherapy Institute — not a one-shot decision. The medical team follows each patient's progress and guides the timing and appropriateness of any subsequent programs.
Who Might Go Straight to the 18-Day
In rare cases — evaluated individually by the medical team — a patient may be a candidate to begin with the 18-day program directly. This is the exception, not the rule. Most patients are best served by the staged approach. If you're unsure which applies to your case, that's exactly what the initial consultation is for.
Shen et al. — Treg cells in Lyme arthritis (Harvard/MGH) — Arthritis & Rheumatism 2010
Dong et al. — UCSF TILT trial: Treg + low-dose IL-2 — JCI Insight 2021
Not sure which program is right for you? That's exactly what a consultation is for.
Gabriela Rodriguez, our Senior Patient Coordinator, will review your complete history and help you understand which path makes the most clinical sense for your situation.
Check My Eligibility